-
Mariann Byerwalter joins Scipher Medicine’s Board of Advisors -
Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study -
18th U.S. Surgeon General Joins Scipher Medicine -
Scipher Medicine and Ambry Genetics Partner to Bring Precision Medicine Test for Rheumatoid Arthritis to Market -
New Strategy for Avoiding Waste and Improving Response for Highest Cost Therapies in Rheumatoid Arthritis -
Clinical utility and cost savings in predicting inadequate response to anti-TNF therapies in rheumatoid arthritis -
Scipher Medicine and Galapagos sign collaboration in inflammatory bowel disease -
Scipher Medicine Announces Publication of Clinical Study Validating PrismRA, a Blood Test Predicting Non-Response to TNF Inhibitor Therapies in Patients with Rheumatoid Arthritis -
Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients -
Scipher Medicine Welcomes Jerry Conway, Appointed Senior Vice President of Market Access -
Pandemic versus pandemonium: fighting on two fronts -
COVID-19 might be bitter medicine for what ails AI investing -
Coronavirus: AI steps up in battle against Covid-19 -
Scipher Medicine has developed a blood test expected to save payers billions each year -
Scipher Medicine Welcomes Chief Technology Officer